October 21, 2024
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma
October 7, 2024
Revolution Medicines to Deliver Multiple Presentations at the 2024 EORTC-NCI-AACR Symposium and Host Investor Webcast
August 7, 2024
Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress
July 31, 2024
Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024
July 11, 2024
Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
July 8, 2024
Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024
June 5, 2024
Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
May 8, 2024
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
May 1, 2024
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024
April 9, 2024
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins